Skip to main content

Same Class, Different Risk? Dapagliflozin versus Empagliflozin and Genitourinary Safety in Heart Failure with Preserved Ejection Fraction: A Retrospective Comparative Cohort Study Cover

.blurhash-client-img { display: none !important; }

Same Class, Different Risk? Dapagliflozin versus Empagliflozin and Genitourinary Safety in Heart Failure with Preserved Ejection Fraction: A Retrospective Comparative Cohort Study

Romanian Journal of Internal Medicine

By: Razvan Alexandru Danau, Madalina Andreea Munteanu, Minerva Muraru, Camelia Nicolae, Gabriel Predoiu, Andreea Bardan and Viorel Jinga

Open Access

|Oct 2026

Figures & tables

Articles in this issue

DOI: https://doi.org/10.2478/rjim-2026-0024 | Journal eISSN: 2501-062X (formerly 1220-4749) | Journal ISSN: 1220-4749

Journal RSS Feed

Language: English, Romanian

Submitted on: Aug 18, 2026

|

Published on: Oct 26, 2026

Published by: N.G. Lupu Internal Medicine Foundation

In partnership with: Paradigm Publishing Services

Keywords:

SGLT2 inhibitor,

heart failure with preserved ejection fraction,

urinary tract infection,

genital infection,

Related subjects:

Clinical medicine,

Internal medicine,

Internal medicine, other,

Gastroenterology,

© 2026 Razvan Alexandru Danau, Madalina Andreea Munteanu, Minerva Muraru, Camelia Nicolae, Gabriel Predoiu, Andreea Bardan, Viorel Jinga, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous article